Chemical dissection of the cell cycle: Probes for cell biology and anti-cancer drug development

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Senese, S ^a   Lo, Y C ^a,b   Huang, D ^b   Zangle, T A ^b   Gholkar, A A ^a   Robert, L ^c   Homet, B ^c   Ribas, A ^c   Summers, M K ^d   Teitell, M A ^a,b,c   Damoiseaux, R ^a   Torres, J Z ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; MI 181; UNCLASSIFIED DRUG; MOLECULAR LIBRARY; MOLECULAR PROBE; TUBULIN;

ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIVISION; CHEMICAL ANALYSIS; CYTOLOGY; M PHASE CELL CYCLE CHECKPOINT; MELANOMA; MICROTUBULE ASSEMBLY; MITOSIS; PRIORITY JOURNAL; ANALYSIS; CELL DEATH; DRUG DEVELOPMENT; DRUG EFFECTS; HELA CELL LINE; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; MOLECULAR LIBRARY; MOLECULAR PROBE; NEOPLASMS; PHARMACOLOGY; PHENOTYPE; POLYMERIZATION; PROCEDURES;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DEATH; DRUG DISCOVERY; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MITOSIS; MOLECULAR PROBES; NEOPLASMS; PHENOTYPE; POLYMERIZATION; SMALL MOLECULE LIBRARIES; TUBULIN;

EID: 84921853680     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.420     Document Type: Article

References (48)

1. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005; 23: 9408-9421.
2. Williams GH, Stoeber K. The cell cycle and cancer. J Pathol 2012; 226: 352-364.
3. Manchado E, Guillamot M, Malumbres M. Killing cells by targeting mitosis. Cell Death Differ 2012; 19: 369-377.
4. Komlodi-Pasztor E, Sackett DL, Fojo AT. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res 2012; 18: 51-63.
5. Neumann B,Walter T, Heriche JK, Bulkescher J, Erfle H, Conrad C et al. Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes. Nature 2010; 464: 721-727.
6. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17: 316-322.
7. Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M et al. The smallmolecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007; 17: 304-315.
8. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol 2012; 6: 155-176.
9. Castoreno AB, Smurnyy Y, Torres AD, Vokes MS, Jones TR, Carpenter AE et al. Small molecules discovered in a pathway screen target the Rho pathway in cytokinesis. Nat Chem Biol 2010; 6: 457-463.
10. Haggarty SJ, Mayer TU, Miyamoto DT, Fathi R, King RW, Mitchison TJ et al. Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis. Chem Biol 2000; 7: 275-286.
11. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999; 286: 971-974.
12. Murphey RD, Stern HM, Straub CT, Zon LI. A chemical genetic screen for cell cycle inhibitors in zebrafish embryos. Chem Biol Drug Des 2006; 68: 213-219.
13. Peters U, Cherian J, Kim JH, Kwok BH, Kapoor TM. Probing cell-division phenotype space and Polo-like kinase function using small molecules. Nat Chem Biol 2006; 2: 618-626.
14. Roberge M, Berlinck RG, Xu L, Anderson HJ, Lim LY, Curman D et al. High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide. Cancer Res 1998; 58: 5701-5706.
15. Wilson CJ, Si Y, Thompsons CM, Smellie A, Ashwell MA, Liu JF et al. Identification of a small molecule that induces mitotic arrest using a simplified high-content screening assay and data analysis method. J Biomol Screen 2006; 11: 21-28.
16. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000; 44: 235-249.
17. Jeon JY, An JH, Kim SU, Park HG, Lee MA. Migration of human neural stem cells toward an intracranial glioma. Exp Mol Med 2008; 40: 84-91.
18. Torres JZ, Summers MK, Peterson D, Brauer MJ, Lee J, Senese S et al. The STARD9/Kif16a kinesin associates with mitotic microtubules and regulates spindle pole assembly. Cell 2011; 147: 1309-1323.
19. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997; 106: 348-360.
20. Tanramluk D, Schreyer A, Pitt WR, Blundell TL. On the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporine. Chem Biol Drug Des 2009; 74: 16-24.
21. Ruegg UTBurgess GM. Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci 1989; 10: 218-220.
22. Osherov N, Gazit A, Gilon C, Levitzki A. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J Biol Chem 1993; 268: 11134-11142.
23. Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci USA 1993; 90: 5889-5892.
24. Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 2001; 10: 2117-2140.
25. Takeuchi N, Nakamura T, Takeuchi F, Hashimoto E, Yamamura H. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem 1992; 112: 762-767.
26. Simon VR, Moran MF. SERCA activity is required for timely progression through G1/S. Cell Prolif 2001; 34: 15-30.
27. Aperia A. New roles for an old enzyme: Na,K-ATPase emerges as an interesting drug target. J Int Med 2007; 261: 44-52.
28. Abbott BJ, Fukuda DS, Dorman DE, Occolowitz JL, Debono M, Farhner L. Microbial transformation of A23187, a divalent cation ionophore antibiotic. Antimicrob Agents Chemother 1979; 16: 808-812.
29. Tsimberidou AM, Alvarado Y, Giles FJ. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev Anticancer Ther 2002; 2: 437-448.
30. Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cellular Signal 2008; 20: 581-589.
31. Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol cancer 2007; 6: 24.
32. Kim HJ, Choo H, Cho YS, No KT, Pae AN. Novel GSK-3beta inhibitors from sequential virtual screening. Bioorg Med Chem 2008; 16: 636-643.
33. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009; 9: 338-350.
34. Clifford B, Beljin M, Stark GR, Taylor WR. G2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res 2003; 63: 4074-4081.
35. Morita T, Yoshino K, Kanazawa T, Ito K, Nose T. Vasodilator action of KB-944, a new calcium antagonist. Arzneimittelforschung 1982; 32: 1037-1042.
36. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4: 191-206.
37. Song JH, Huang CS, Nagata K, Yeh JZ, Narahashi T. Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther 1997; 282: 707-714.
38. Wagner ML, Landis BE. Riluzole: a new agent for amyotrophic lateral sclerosis. Ann Pharmacother 1997; 31: 738-744.
39. Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther 2002; 1: 1201-1209.
40. Chavarria AP, Swartzwelder JC, Villarejos VM, Zeledon R. Mebendazole, an effective broadspectrum anthelmintic. Am J Trop Med Hyg 1973; 22: 592-595.
41. Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 2008; 132: 487-498.
42. Hutchins JR, Toyoda Y, Hegemann B, Poser I, Heriche JK, Sykora MM et al. Systematic analysis of human protein complexes identifies chromosome segregation proteins. Science 2010; 328: 593-599.
43. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012; 11: 873-886.
44. Salama AK, Kim KB. Trametinib (GSK1120212) in the treatment of melanoma. Expert Opin Pharmacother 2013; 14: 619-627.
45. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-265.
46. Sondergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010; 8: 39.
47. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999; 4: 67-73.
48. Torres JZ, Ban KH, Jackson PK. A specific form of phospho protein phosphatase 2 regulates anaphase-promoting complex/cyclosome association with spindle poles. Mol Biol Cell 2010; 21: 897-904.